Change Agents Corporation. (CHGA): director Eric Weisblum elected to the board

Events in this filing

Item 5.02 as filed

Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On October 14, 2026, Change
Agents Corporation (the “Company”) appointed Eric Weisblum as an independent director
on the Company’s board of directors, effective October 12, 2026. Mr. Weisblum will serve on each of the Audit, Compensation and
Nominating and Corporate Governance Committees.
Eric
Weisblum brings decades of investment banking, capital markets and public company management experience. Since 2020 Mr. Weisblum has
been the Chief Executive Officer of Silo Pharma Inc, a biopharmaceutical company that he founded. Prior to Silo Pharma Mr. Weisblum
was a private investor, board member, and advisor to several companies. Mr. Weisblum has experience in both licensing therapeutic
assets and assisting in their development. As a result, Mr. Weisblum brings with him nearly 20 years of experience in structuring
and trading financial instruments. Mr. Weisblum was a registered representative with Domestic Securities, a New Jersey-based
broker-dealer. While with Domestic Securities, Mr. Weisblum held the Series 7 - General Securities Representative, the Series 63
– Uniform Securities Agent State Law Examination, and the Series 55 – Registered Equity Trader securities registrations.
From 1993 to 2002, Mr. Weisblum originated, structured, traded, and placed structured financing transactions at M.H. Meyerson &
Co. Inc., a publicly-traded registered investment bank. He holds a B.A. from the University of Hartford’s Barney School of
Business.
The Company believes Mr. Weinblum is suited to act as a Company Director due to his significant public company and capital markets experience.
There
is no arrangement or understanding between Mr. Weisblum and any other person, other than the Company’s directors acting solely
in their capacity as such, pursuant to which he was selected as a director of the Company. Mr. Weisblum is not related by blood, marriage
or adoption to any director or executive officer.
The
Company is not aware of any transaction, or currently proposed transaction, in which the Company was or is to be a participant and in
which Mr. Weisblum, or any member of his immediate family, had or will have a direct or indirect material interest that would be required
to be reported under Item 404(a) of Regulation S-K.
- 1 -